New study tracks nasal IVIG for long COVID in Immune-Weakened patients

NCT ID NCT06992401

Not yet recruiting Knowledge-focused Sponsor: Tamara C Tamas Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how intranasal IVIG (a treatment given through the nose) might help people with Long COVID who also have a weak immune system. Researchers will collect health data from 50 participants, but no treatment is given as part of the study. The goal is to see if this approach can reduce symptoms like fatigue, brain fog, and inflammation. All treatment decisions are made by each clinic independently.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID 19 ASSOCIATED COAGULOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disseminated intravascular coagulation immunodeficiency disease long COVID-19 Mental Fatigue

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID 19 ASSOCIATED COAGULOPATHY COVID-19 VACCINATION LONG COVID LONG COVID FATIGUE LONG COVID SYNDROME POST ACUTE SEQUELAE OF SARS COV 2 INFECTION

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.